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Abstract
RB1-inducible coiled-coil 1 (RB1CC1, also known as FIP200) plays a role in the enhancement of the RB1 pathway through the
direct binding to a GC-rich region 201bp upstream (from the initiation ATG) of the RB1 promoter. Here, we identified hSNF5
and p53 as the binding partners of RB1CC1 by immunoprecipitation and immunofluorescence assays. Interaction between
these molecules and the RB1 pathway was analyzed by the assays of chromatin immunoprecipitation, luciferase-reporter,
reverse transcription-polymerase chain reaction and immunoblot. The tumor growth suppression by RB1CC1 was evaluated
by flow cytometry or by a cell growth assay. The nuclear RB1CC1 complex involving hSNF5 and/or p53 activated
transcription of RB1, p16 and p21, and suppressed tumor cell growth. Furthermore, nuclear RB1CC1 expression significantly
correlated with those of RB1 and p16 in breast cancer tissue in vivo, and the Ki-67 proliferation index was dependent on p53
as well as RB1CC1. The present study indicates that RB1CC1 together with hSNF5 and/or p53 enhances the RB1 pathway
through transcriptional activation of RB1, p16 and p21. Evaluation of RB1CC1 expression combined with RB1 and p53 status
is expected to provide useful information in clinical practice and future therapeutic strategies in breast cancer.
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Introduction
The retinoblastoma tumor suppressor protein (RB1) regulates
G1/S-phase cell cycle progression and is a critical mediator of
antiproliferative signaling. Although phosphorylation plays an
important role in the functional regulation of RB1, the
transcriptional regulation of RB1 is much less known [1]. RB1-
inducible coiled-coil 1 (RB1CC1: the symbol used here, which is
approved by the Human Genome Organization [HUGO] Gene
Nomenclature Committee; it is also known as FIP200, focal
adhesion kinase family-interacting protein of 200 kDa) was
identified as an RB1 pathway regulator that in particular enhances
RB1 transcription [2,3]. Recently, we have demonstrated that
nuclear RB1CC1 binds to a GC-rich region 201bp upstream
(from the initiation ATG) of the RB1 promoter and activates the
expression of RB1 [4]. A genetic rearrangement of RB1CC1 has
also been suggested to be involved in the tumorigenesis of breast
cancer [3,5]. Interestingly, it has been reported that RB1CC1
binds and stabilizes p53 [6], suggesting that RB1CC1 might be an
important mediator connecting the RB1 and p53 pathways. Our
present study investigates the mechanism of RB1CC1 enhance-
ment of the RB1 pathway. RB1CC1 forms a complex with p53
and/or hSNF5, a chromatin-remodeling factor, in cell nuclei, and
activates the transcription of RB1, p16 and p21. In addition,
nuclear RB1CC1 significantly correlates RB1 and p16 expression
in breast cancer tissue in vivo.
Results
RB1CC1 forms a complex with hSNF5 and/or p53
We initially attempted to identify RB1CC1-binding proteins in
MCF-7 breast cancer cells by an immunoprecipitation assay
followed by liquid chromatography-tandem mass spectrometry
(LC-MS/MS). A chromatin remodeling factor, hSNF5 (also
known as BAF47 or INI1) was co-immunoprecipitated with
RB1CC1 (Fig. 1A). The pull-down assay using RB1CC1 deletion-
mutants revealed that the C-terminal region of RB1CC1 (aa
1364–1594) was required for the interaction with hSNF5 (Fig. 1B
and C). The N-terminus of RB1CC1 also interacts with p53 [6], so
we considered that RB1CC1 might form a complex with hSNF5
and/or p53 to inhibit tumor growth. The complex formation
between RB1CC1, hSNF5 and p53 was evaluated by immuno-
precipitation and immunofluorescence assays. RB1CC1, hSNF5
and p53 were co-immunoprecipitated with two kinds of antibodies
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11404Figure 1. RB1CC1 forms a complex with hSNF5 and/or p53. (A) MCF-7 cell lysates were immunoprecipitated (IP) with anti-RB1CC1 antibody
and analyzed by SDS-PAGE followed by silver staining. The molecule that co-immunoprecipitated with RB1CC1 was identified as hSNF5 by liquid
chromatography-tandem mass spectrometry (LC-MS/MS). (B) Flag-RB1CC1 and HA-hSNF5 were co-transfected into HEK293 cells. Lysates were
immunoprecipitated with anti-Flag or anti-HA antibody, and analyzed by immunoblots as indicated. Arrowheads indicate the co-immunoprecipitated
signals. (C) HEK293 cells were transfected with both HA-hSNF5 wildtype (full) and Flag-RB1CC1 variants; wildtype (wt), dccA, dccB, dLZ, LZC, dCC and
Fcc. Schematic diagrams of RB1CC1wt and mutants are also indicated on the left side. The rectangle shows the binding site for hSNF5, and the
broken rectangle indicates that for p53. Cell lysates were immunoprecipitated with anti-HA antibody and immunoblotted as indicated. (D) MCF-7
lysates were immunoprecipitated with two kinds of anti-RB1CC1 antibody and analyzed by immunoblots. (E) RB1CC1 (green), hSNF5 (red), p53 (blue)
and the merged image in HeLa cells. Each protein is immunofluorescently labeled by Alexa 488, 594 or 350 respectively. Scale bar, 50 mm. (F) RB1CC1
(green), DAPI and the merged image in HeLa cells. RB1CC1 is immuno-labeled by Alexa 488, and DAPI is displayed with blue fluorescence in cell
nuclei. Scale bar, 50 mm.
doi:10.1371/journal.pone.0011404.g001
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the composition of each of the precipitates is different, probably
due to the preferable fractions to each antibody (Fig. 1D).
RB1CC1-1 and -2 antibodies have tended to bind more preferably
to the nuclear and cytoplasmic fractions, respectively. hSNF5 and
abundantly nuclear p53 (that might be more phosphorylated and
slowly mobilized in PAGE) might be preferably co-precipitated
with the complex between nuclear RB1CC1 and RB1CC1-1
antibody. Reciprocally, RB1CC1-2 antibody might dominantly
bind to abundant cytoplasmic RB1CC1 as well as hSNF5 and a
few of p53 in cytoplasm. RB1CC1, hSNF5 and p53 were co-
localized in cell nuclei with the exception of nucleoli (Fig. 1E and
F; Fig. S1). The data indicated that RB1CC1 forms a complex
with hSNF5 and/or p53 mainly in cell nuclei.
RB1CC1 binds to and activates the promoters of RB1, p16
and p21, cooperating with p53 and/or hSNF5
RB1CC1 [2,4,6] and hSNF5 [7,8,9,10] enhance transcription
of the molecules involved in the RB1 pathway, so we examined
whether RB1CC1, hSNF5 and p53 bind to the promoter regions
of RB1, p16 and p21. Chromatin immunoprecipitation (ChIP)
assays using antibodies against RB1CC1, hSNF5 and p53
indicated that promoter fragments of RB1, p16 and p21, which
were amplified from HeLa cell chromatin, were precipitated by
each antibody (Fig. 2A), suggesting that the molecules are
recruited to the promoter regions of the RB1 pathway. The
involvement of these three molecules in the expression of RB1, p16
and p21 were validated by introducing sh-RNA for RB1CC1 (sh-
RB1CC1), hSNF5 (sh-hSNF5) and p53 (sh-p53) into HeLa cells. The
knockdown effects on RB1CC1, hSNF5, p53, p21, p16 and RB1
mRNA expression were analyzed by semi-quantitative RT-PCR.
sh-RB1CC1 and sh-hSNF5 decreased mRNA levels of RB1, p16
and p21, whereas sh-p53 decreased only p21 mRNA (Fig. 2B). In
other words, RB1CC1 and hSNF5 are required to maintain
transcriptions of RB1, p16 and p21, whereas p53 is specifically
required for transcription of p21. RB1CC1 significantly activated
the promoters of RB1, p16 and p21 (Fig. 2C), and the knockdown
of RB1CC1 suppressed them (Fig. 2D). These promoter
enhancements by RB1CC1 were compared among HeLa,
TTC642 (hSNF5-null) and H1299 (p53-null) cells, in order to
validate the requirement for hSNF5 or p53 when RB1CC1
activates RB1, p16 and p21. RB1CC1 was unable to provide
significant enhancement of RB1 and p16 promoters in TTC642
cells, and played only a small role in p16 and p21 transcription in
H1299 cells (Fig. 2E). Considering the RB1 pathway initiated by
RB1CC1, RB1CC1 requires hSNF5 for enhancement of RB1 and
p53 for enhancement of p21 transcriptions, but both hSNF5 and
p53 are needed for RB1CC1 enhancement of p16 transcription. In
summary, RB1CC1 requires interaction with both hSNF5 and
p53 to provide a strong activation of RB1, p16 and p21 promoters.
RB1CC1 activates the RB1 pathway and suppresses
tumor growth
To evaluate whether RB1CC1 enhances RB1 pathways to
suppress cancer cell growth, HeLa cells were lentivirally
transduced with RB1CC1 cDNA or shRNA. Ectopic expression
of RB1CC1 increased the protein levels of p53, p21, p16 and RB1,
and inhibited the cell growth (Fig. 3A and B, left panel). In
contrast, the knockdown of endogenous RB1CC1 by sh-RB1CC1
decreased the levels of p53, hSNF5, p21 and p16, and enhanced
the cell growth (Fig. 3A and B, right panel). The same experiments
in two breast cancer cell lines (MCF-7 and SK-BR3) yielded
similar results (Fig. S2A-D). In RB1CC1-transduced cells, the
number of G0/G1-phase-cells was increased concomitantly with
the decrease of the numbers of cells in S and G2/M phases.
Introduction of sh-RB1CC1 decreased the G0/G1 population and
increased the populations of cells in S and G2/M (Fig. 3C; Fig.
S2E).
Taken together, the above-mentioned data indicated that
RB1CC1 formed a complex with hSNF5 and/or p53, and
globally activated the transcription of RB1, p16 and p21 (Fig. 3D).
Expressional analysis of the molecules involved in the
RB1CC1-RB1 pathway in breast cancers in vivo
To evaluate the correlation between the proliferative activity
and the above-mentioned RB1CC1 pathway of RB1 activation
involving p53 and hSNF5 in tumor tissue in vivo, we evaluated the
expressional status of RB1CC1, RB1, p16, p21, Ki-67, p53 and
hSNF5 in 59 cases of breast cancer. Four cases of RB1 nullizygotes
indicated a high Ki-67 proliferation index (means 6 standard
errors=69.766.6%). The immunoreactivity of p53—referring to
p21 expression—was divided into two categories, ‘‘normal’’
(p53nor) for weak staining and ‘‘abnormal’’ (p53ab) for strong
staining, which highly indicated that mutant p53 protein was
accumulated. There were 41 and 14 cases of p53nor and p53ab,
respectively, in this series. hSNF5 was highly maintained in breast
cancers, irrespective of RB1CC1 or p53 status (data not shown).
The immunohistochemical results for RB1CC1 were quantita-
tively graded as I-III. Grade III, expressing RB1CC1 abundantly
in cell nuclei, was recorded as RB1CC1 (+), whereas grades I–II
without nuclear RB1CC1 were recorded as (2) (Fig. 4A). As
reported previously [4], the expression of RB1 was quite well
correlated with RB1CC1 expression in the cases recorded as
RB1CC1 (+) and was higher than in the RB1CC1 (2) cases
(Fig. 4B, left). p16 expression was also correlated positively with
nuclear RB1CC1 expression (Fig. 4B, 2
nd left). Labeling indices of
p21 and Ki-67 in p53nor cases - but not in the p53ab cases - were
well correlated with the expression status of RB1CC1 (Fig. 4B, 3
rd
left and right). Together, the expression status of RB1CC1 and
p53 were associated with increased expressions of RB1, p16 and
p21, which in turn influenced the Ki-67 index of proliferation
activity in clinical breast cancers. Therefore, the immunohisto-
chemical status of RB1 and p53 as well as that of RB1CC1 should
be good predictors of the proliferative activity; thus, the RB1CC1-
RB1 pathway demonstrated in our experiments could play a
significant role in the progression of clinical breast cancer.
Discussion
RB1CC1 is a novel regulator of RB1 that dephosphorylates
RB1 [2,6] and increases its expression [2,4]; in addition, a genetic
rearrangement of RB1CC1 might be involved in breast cancer
tumorigenesis [3,5]. More recently, we reported that nuclear
RB1CC1 directly activates the RB1 promoter through a 201bp
upstream GC-rich region (2201/U-GCbox) [4]. To clarify more
precisely the molecular mechanism of the RB1CC1 action, an
immunoprecipitation assay followed by LC-MS/MS was attempt-
ed, and a chromatin remodeling factor, hSNF5 was identified.
RB1CC1 also interacts with p53, so RB1CC1 is thought to form a
complex with hSNF5 and/or p53. It is thought that RB1CC1
induces RB1 [2,4], and that hSNF5 enhances p16 (also known as
INK4a or CDKN2A) and/or p21 (also known as CIP1, WAF1 or
CDKN1A) [7,8,9,10]. In fact, immunoprecipitation and immu-
nofluorescence assays have indicated that a complex between
RB1CC1, hSNF5 and p53 forms in cell nuclei, and ChIP,
quantitative RT-PCR and the luciferase assays for RB1, p16 and
p21 have suggested that the coordinated transcriptional enhance-
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RB1CC1, hSNF5 and p53. However, RB1CC1, hSNF5 and p53
are not equally important to the stimulation of each of the
promoters of RB1, p16 or p21, while three molecules are recruited
to each promoter. For example, silencing p53 in HeLa cells had no
effect on the transcription of RB1, and RB1CC1 over-expression
can activate the RB1 promoter in H1299 (p53-null) cells. These
mean that p53 isn’t essentially required to RB1 transcription, and
that RB1CC1 and hSNF5 can co-operate to activate RB1
transcription. Thus, all three molecules are not always required
for activation of each of the promoters, while all three are needed
for the coordinated transcriptions of RB1, p16 and p21. We have
also established earlier that nuclear RB1CC1 binds to and
activates the RB1 promoter [4]. Interestingly, a point-mutation
in the 2201/U-GCbox of the RB1 promoter was identified in a
hereditary retinoblastoma family [11]. It should be pointed out
that the 2201/U-GCbox of RB1 and the binding transcriptional
complex that includes RB1CC1, hSNF5 and p53 play important
roles in human carcinogenesis.
In the present study, RB1CC1, in collaboration with hSNF5
and p53, activates the RB1 pathway and suppresses tumor cell
growth. In order to activate the RB1 pathway effectively,
RB1CC1 must be expressed in cell nuclei and should form a
complex with hSNF5 and/or p53, as suggested in the immuno-
cytochemical and immunohistochemical data of this study. PIASy
(a protein-inhibitor of activated STAT protein y) interacts with the
C-terminus (aa 1350–1594) of RB1CC1 and recruits an
interacting complex between PIASy and RB1CC1 from cytoplasm
into nuclei [12]. In addition, PIASy negatively regulates
mammalian target of rapamycin (mTOR) activity stimulated by
cytoplasmic RB1CC1, and positively activates the p53-p21
signaling pathway together with nuclear RB1CC1 [12]. These
data seem to be compatible with our presented data on the
sublocalization of the complex composed of RB1CC1, hSNF5 and
p53. The nuclear molecular complex, including RB1CC1, hSNF5,
p53 and additional PIASy, can form a large transcriptional
component to activate the RB1 pathway coordinately and repress
the tumorigenesis in human breast tissue.
Nuclear expression of RB1CC1 could be important for tumor
suppression. As reported previously, RB1CC1 is located not only
in the nucleus but also in the cytoplasm [4,6,13,14]. Cytoplasmic
RB1CC1 has been suggested to be the equivalent of yeast Atg17,
and several studies have indicated that RB1CC1 functions as an
essential molecule in autophagy regulation [13,14,15]. Autophagy
has been implicated in tumorigenesis, but its precise role is
ambiguous. It is conceivable that autophagy has different roles in
the different stages, or contexts, of tumorigenesis. Young, et al.
[16] have reported that autophagy mediates the mitotic senes-
cence, a window into early tumor development. We suggest that
cytoplasmic-nuclear transition of RB1CC1 plays a key role in
autophagy-senescence association. Our data in vitro and in vivo
suggest that RB1CC1 plays different roles according to its
subcellular location. Nuclear RB1CC1 forms a complex with
hSNF5, p53 and any other component that contributes to the
transcription of the RB1 pathway, indicating a possible linkage to
mitotic senescence. However, cytoplasmic RB1CC1 seems to play
no role as a tumor suppressor activating the RB1 pathway.
Nuclear RB1CC1 expression significantly correlated with those
of RB1 and p16 in breast cancer tissue in vivo, irrespective of p53
status. Ki-67 proliferation index and p21 expression were affected
by both RB1CC1 and p53, and the Ki-67 index also depended on
RB1 status. The expressions of RB1, p16 and p21 affect the Ki-67
index of proliferative activity, so the immunohistochemical status
of RB1 and p53 as well as that of RB1CC1 can predict the
proliferative activity of the tumor. Thus, the present data
suggested that progression of the breast cancers was under the
strong influence of RB1CC1, as well as RB1 and p53 status. We
expect that the combined immunohistochemical evaluation of
RB1, RB1CC1 and p53 will provide insight into their clinical
applications, such as possible use as prognostic biomarkers.
In summary, we have reported here that RB1CC1, connecting
the RB1 and p53 pathways as a possible mediator, forms a
complex with hSNF5 and/or p53 that enhances the RB1 pathway
globally. Immunohistochemical evaluation of RB1 and p53 in
combination with RB1CC1 may be a useful biomarker in
convenient, routine clinical assays and provide a prediction of
the biological behavior of breast neoplasms and/or the tumors of
other organs.
Materials and Methods
Cell culture
TTC642 was kindly provided by Drs. Shigeru Ohta, Hiroyuki
Shimada and Timothy J. Triche (Childrens Hospital Los Angeles,
Los Angeles, CA). HeLa, HEK293, MCF-7, SK-BR3 and H1299
cells were purchased from American Type Culture Collection
(MD), and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) or RPMI 1640 containing 10% fetal bovine serum. All
cell culture media were supplemented with penicillin (50 units/ml)
and streptomycin (50 mg/ml).
Antibodies and reagents
Rabbit antisera against RB1CC1 (aa. 25–271, 549–817 as each
epitope) were generated as previously reported [4,17], and the
purified IgG were used in the experiments. Anti-p53 (FL-393) and
anti-p21 (F-5) were obtained from Santa Cruz Biotechnology (CA).
Anti-HA (3F10) was from Roche (Germany). Anti-Flag (M2) and
anti-tubulin a (DM 1A) were purchased from Sigma (MO). The
other antibodies were from BD Biosciences (CA).
Figure 2. RB1CC1 binds to and activates the promoters of RB1, p16 and p21, cooperating with p53 and/or hSNF5. (A) Chromatin
immunoprecipitation (ChIP) assay was performed in HeLa cells. The chromatin was immunoprecipitated by anti-RB1CC1, anti-p53, or anti-hSNF5
antibody. Each precipitated DNA was analyzed by quantitative and semi-quantitative PCR using the promoter-specific primers for RB1, p16 and p21.
The signal intensities were defined based on those originating from input DNA (2ng/ml) of HeLa cells, which were set as 1,000. (B) Semi-quantitative
RT-PCR was performed at the individual cycle number for each transcript in HeLa cells treated with shRNA for RB1CC1, hSNF5 or p53. Sh-GL3, sh-p21
and sh-p16 were used as controls. Parentheses indicate the PCR cycle numbers. (C–D) In HeLa cells, luciferase activity of the promoter for RB1, p16
and p21 increased significantly upon transfection of plasmid expressing RB1CC1 (RB1CC1wt) (C) and decreased markedly upon knockdown of RB1CC1
using sh-RB1CC1-1 and -2 (D), compared with cells transfected with pcDNA or sh-RNA scramble, respectively, as controls. The values indicate the
means 6 standard errors from quadruplicate experiments. (Student’s t-test; asterisks (*) indicate statistically significant differences between pcDNA
and RB1CC1wt or between scramble and sh-RB1CC1.* ,p ,0.05; and **, p,0.01). The efficiency of over-expression or knockdown of RB1CC1 was
validated by Western blots as indicated in the upper panels. (E) After the introduction of RB1CC1wt, luciferase activities of the promoters for RB1, p16
and p21 were compared among HeLa, TTC642 (hSNF5-null) and H1299 (p53-null) cells. Asterisks (**) indicate statistically significant differences
(Student’s t-test; p,0.01) between HeLa and TTC642 or between HeLa and H1299.
doi:10.1371/journal.pone.0011404.g002
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PLoS ONE | www.plosone.org 5 June 2010 | Volume 5 | Issue 6 | e11404Figure 3. RB1CC1 activates the RB1 pathway and suppresses tumor growth. (A) HeLa cells were lentivirally transduced with RB1CC1 or sh-
RB1CC1. Lysates were immunoblotted as indicated. (B) Growth assays in HeLa cells transduced as in a. The data were quantified from triplicate
experiments (lower column). Representative immunoblots, plates and mean colony numbers 6 standard errors are shown. (C) After the lentiviral
modification of RB1CC1 expression, NIH3T3 cells were analyzed by flow-cytometry. RB1CC1 and sh-RB1CC1 are indicated by red (left) and blue (right),
respectively. The data (mean percentages 6 standard deviations) were confirmed in triplicate experiments, and a representative flow cytometric
graph is demonstrated. pLenti6 and sh-GL3 were used as controls. Arrows indicate that increases (up-arrow) and decreases (down-arrow) were
statistically significant according to the Student’s t-test; p,0.05 (D) RB1CC1, hSNF5 and p53 form the transcriptional complex in cell nuclei, and
activate RB1, p16 and p21.
doi:10.1371/journal.pone.0011404.g003
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liquid chromatography- tandem mass spectrometry (LC-
MS/MS)
The MCF-7 breast cancer cells were lysed in EBC lysis buffer
containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40 (NP-40), 0.25% sodium deoxycholate,
0.2 mM Na3VO4, 100mM NaF and 1% protease inhibitor
cocktail (Wako Chemicals, Japan), and then centrifuged for
20 min at 20,0006ga t4 uC. The 5 ml supernatant (,10mg/ml)
was incubated with 100 mg of anti-RB1CC1 purified IgG primary
antibody at 4uC overnight. The immunocomplexes were bound to
protein G-agarose (Pierce, IL) for additional 2 h at 4uC and
washed five times with NETN (20mM Tris-HCl (pH 8.0),
100 mM NaCl, 1 mM EDTA, 0.5% NP-40). The proteins bound
to the protein G-Sepharose were eluted by adding Laemmli SDS
Figure 4. In vivo significance of RB1CC1. (A) The immunohistochemical grades of RB1CC1 were classified as I–III: I, negative stain in both
cytoplasm and nuclei; II, positive stain only in cytoplasm and negative in nuclei; III, positive stain in nuclei and/or cytoplasm. Grades III, expressing
RB1CC1 abundantly in cell nuclei, were recorded as RB1CC1 (+), whereas grades I–II without nuclear RB1CC1 were recorded as RB1CC1 (2). Scale bar
shows 50mm. (B) Correlation between RB1CC1 and RB1, p16, p21 or Ki-67 in p53normal (upper graphs) and abnormal (lower graphs) cases. RB1CC1
(2)o r( +) status is indicated on the horizontal line, and each labeling index is indicated on a vertical line in the graphs. An abnormal p53 status was
defined as a case of breast cancer when more than 50% of tumor cells were strongly positive for p53, while less than 10% of the cells were positive
for p21. Such case highly indicated that mutant p53 protein was accumulated, and that the intact functions of p53 (like transcriptional activation for
p21) were loss. Student’s t-test was used to evaluate the correlations (*, p,0.05; and **, p,0.01).
doi:10.1371/journal.pone.0011404.g004
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glycerol, 5% 2-mercaptoethanol, 2% SDS, and 0.01% bromo-
phenol blue to the gel and boiling it for 3 min. After centrifugation
at 10,0006g for 2 min, the supernatant was subjected to SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), and the separat-
ed proteins were visualized by silver staining. The strongly stained
specific band was in-gel digested with trypsin, and the recovered
peptides were analyzed using an electrospray ion-trap mass
spectrometer (LCQ, Finnigan MAT, CA) coupled online with
capillary HPLC (Magic 2002, Michrom BioResorces, CA) to
acquire mass spectrometry/mass spectrometry (Ms/Ms) spectra.
Data derived from the Ms/Ms spectra were used to search a
compiled protein database, which was composed of database NR
and a six-reading-frame translated EST database, to identify the
protein by using the publicly available program PROWL (http://
prowl.rockefeller.edu).
Plasmid DNA and gene transfer
External and internal deletion mutants for RB1CC1 (GenBank
no. NM_014781) were generated in the pcDNA3.1 plasmid vector
(Invitrogen), by a combination of PCR-based manipulations with
appropriate external primers at the positions described below and
restriction enzyme digestion. The nucleotides of all constructs were
confirmed by DNA sequencing. The RB1CC1 mutants dccA,
dccB, dLZ, LZC, dCC and Fcc deleted the amino acids 863–1083,
1078–1363, 1364–1594, 1–1356, 824–1594 and 1–863, respec-
tively (Fig. 1C, left panel). Transfection was performed using
FuGENE HD (Roche) according to the supplier’s recommenda-
tions. Plasmid vectors of RNAi for RB1CC1 were prepared as
described previously [17]. Briefly, two kinds of lentiviral sh-RNA
vectors (sh-RB1CC1-1 and -2) corresponding to different target
sites (nt. 2070–2090 and nt. 4611–4631, respectively) on RB1CC1
mRNA (GenBank no. NM_014781) were synthesized in vitro by
inserting artificial oligonucleotides into the pSIH1-H1-Puro sh-
RNA vector (System Biosciences, CA). Vectors for sh-RNA of
hSNF5 and p53 were prepared by OpenBiosystems (AL). For non-
silencing controls, sh-GL3 and scramble vectors were purchased
from System Biosciences and OpenBiosystems, respectively.
Additionally, human RB1CC1 cDNA was subcloned into a pLenti6
vector (Invitrogen). Lenti-virus transferring sh-RNA or cDNA was
prepared with each packaging mix, according to each manufac-
turer’s instructions. Cloned and expanded cells were selected in
the presence of puromycin or blasticidin, respectively, and used in
the experiments.
Pull-down assay
Flag-tagged-wildtype (wt) RB1CC1 or its mutants (dccA, dccB,
dLZ, LZC, dCC and Fcc) were transfected into HEK293 cells
combined with HA-tagged hSNF5 (full). The cells were lysed in
TNE buffer (20 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1%
NP-40 and 1 mM Na3VO4 containing a mixture of protease
inhibitors). The lysates were centrifuged, and the supernatants
were incubated with anti-Flag or anti-HA immobilized beads for
2 h at 4uC. The beads were washed five times with TNE buffer
and boiled in the presence of Laemmli SDS sample buffer. The
protein complexes were resolved by SDS-PAGE, transferred to
PVDF membrane filters and subjected to immunoblot analysis
with the indicated antibodies.
Immunoprecipitation to detect the protein complex
MCF-7 monolayer cells were rinsed with ice-cold phosphate-
buffered saline (PBS) and scraped into ice-cold NP-40 lysis buffer
(20 mmol/L Tris (pH 8.0), 137 mmol/L NaCl, 1% NP-40, 10%
glycerol) supplemented with 1% protease inhibitor cocktail (Wako
Chemicals) and 3 mmol/L Na3VO4. Lysates were incubated on
ice for 20 minutes, cleared by centrifugation, and protein
concentration was determined by the bicinchoninic acid assay
(Pierce). Solutions containing 400 to 1,000 mg of protein were
briefly precleared with protein-G-agarose beads (Pierce) and then
used for the immunoprecipitation reaction with 2 kinds of anti-
RB1CC1 rabbit polyclonal IgGs or normal control rabbit IgGs at
4uC overnight, followed by incubation with protein-G beads for
2 hours to collect immune complexes. Finally, the beads were
washed with NP-40 buffer five times, resuspended in SDS sample
buffer, boiled, resolved on SDS-PAGE, and analyzed by
immunoblots as described below.
Immunoblot analysis
Cells were generally lysed for Western blotting as described by
Sarbassov, et al [18]. After clearing lysed materials by centrifu-
gation at 15,0006g for 1 min, the supernatants were boiled in
SDS sample buffer. Proteins resolved by SDS-PAGE were
transferred to polyvinylidene difluoride (PVDF) filters. After
blocking of the filters with TBS-T (10 mM Tris-HCl (pH 7.6),
150 mM sodium chloride, 0.1% Tween 20) containing 5% bovine
serum albumin (BSA), the filters were incubated overnight with the
indicated primary antibodies in TBS-T containing 2% BSA at
4uC. The filters were then washed in TBS-T and incubated for 1 h
in horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or
anti-rat IgG (GE Healthcare, UK) diluted 1:20,000 in TBS-T
containing 2% BSA. After several washes with TBS-T, the
immunoreactivity was detected using the ECL system (GE
Healthcare) according to the procedures recommended by the
manufacturer.
Immunofluorescence assay
MCF-7 and HeLa cells were cultured on LabTek
TM chamber
slides (BD Biosciences) to 70% confluence, fixed with 1% buffered
formaldehyde and 70% ethanol, and then permeabilized with
0.1% Triton X-100. The primary rabbit anti-RB1CC1 IgG,
mouse anti-hSNF5 IgG2a (BAF48), and rabbit anti-p53 IgG
(FL393) were conjugated with Alexa 488, 594 and 350 by the
ZenonTM labeling kit (Molecular Probes). To evaluate the
subcellular location, 49,6-diamidino-2-phenylindole (DAPI) was
also applied in HeLa and MCF-7 cells. The labeled primary
antibodies were incubated overnight at 4uC. The slides were then
washed with PBS to remove excess fluorescent dye and mounted
with glycerol. The specimens were observed and photographed
under identical conditions using a confocal laser-scanning
microscope (C1si, Nikon Co.).
Chromatin immunoprecipitation (ChIP) assay
For ChIP of the endogenous RB1, p21 and p16 promoter
regions in HeLa cells, the ChIP-IT
TM control kit and ChIP-IT
TM
Express (Active Motif, CA) were used, and the assay performed
essentially as described in the Active Motif protocol. The used
antibodies were anti-RB1CC1, anti-hSNF5 (BAF48), anti-p53
(FL-393) and control rabbit IgG (Active Motif). The immunopre-
cipitated DNA was quantified by the quantitative (Real-time) and
semi-quantitative polymerase chain reaction. The amplified
promoter regions of RB1 and p16 were from 2385 to 2110,
and from 2712 to 2529, respectively (the first ATG was defined
as +1). For the p21 promoter, the region from 22432 to 22175
(the transcriptional start site was defined as +1) was amplified. The
sequences of the PCR primers and suitable PCR conditions are
available upon request.
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in the specifically knocked-down cells for RB1CC1, hSNF5
or p53
Transcriptional expressions of RB1, p21 and p16 were evaluated
by the semi-quantitative reverse transcription-polymerase chain
reaction (RT-PCR) method between sh-GL3 control and the gene-
specific knocked-down HeLa cells, transfected lentivirally with
shRNA for RB1CC1 (sh-RB1CC1), hSNF5 (sh-hSNF5) and p53 (sh-
p53). Transcribed mRNA in each knocked-down cell was
adequately quantified by semi-quantitative RT-PCR at the
individual cycle number for each transcript. The sequences of
the PCR primers and suitable RT-PCR conditions are available
upon request.
Luciferase-reporter assay
HeLa, TTC642 (hSNF5-null) and H1299 (p53-null) cells were
seeded at 0.7610
5 cells/well in 6-well plates. On the next day,
RB1-, p21-, or p16-luciferase reporter plasmid was cotransfected by
FuGENE HD (Roche) with plasmids empty vector and/or
RB1CC1-cDNA, -shRNA vector. Twenty-four hours later, cells
were lysed, and luciferase activity was analyzed using a Luciferase
assay kit (Toyo Ink, Japan) and luminometer (EG&G Berthold
Lumat LB 9507). The p16 promoter region from 2900 to 222
(the first ATG was defined as +1) was contained in the luciferase
reporter plasmids (pGL3, Promega, WI). RB1- and p21-luciferase
plasmids were constructed as reported previously [2,19].
Cell cycle analysis
To analyze the cell cycle between pLenti6 control and
RB1CC1-expression; sh-GL3 control and RB1CC1-knockdown
cells, the distribution of DNA content was measured using the
CycleTEST
TM PLUS kit (Becton Dickinson). Flow cytometric
data were collected on a FACSCaliber, and analyzed with
CellQuest software.
Cell growth assay
The cells were prepared at 1610
5 cells/well in 6-well plates,
lentivirally transduced with cDNA or shRNA for RB1CC1, and
incubated in the presence of blasticidin or puromycin, respectively.
After 10–20 days of transduction, the cells were fixed with 10%
acetate/10% methanol for 20 minutes, and stained with 0.4%
crystal violet in 20% ethanol for 15 minutes to visualize the
colonies.
Patients and histology
A total of 72 consecutive patients with operable primary breast
cancers, treated in Shiga University of Medical Science or in
Osaka Medical Center for Cancer and Cardiovascular Diseases
around 1999, were studied. Among these, we failed to assess the
immunohistochemical evaluations in 13 tumor specimens as a
result of tissue loss during slide preparation. Therefore, specimens
from 59 patients with primary breast cancer were analyzed in this
study. They were collected with the written informed consent of
patients, and after approval by the Ethics Committee of Shiga
University of Medical Science. The pathological diagnoses of all
the specimens were confirmed by at least two surgical pathologists,
and classified according to the World Health Organization
(WHO) guidelines.
Immunohistochemistry
To evaluate RB1CC1, RB1, p16, p21, Ki-67, p53 and hSNF5
in human breast cancer tissues, surgical specimens from 59 cases
were transferred to 10% buffered formalin and fixed overnight.
The fixed samples were embedded in paraffin and serially sliced
into 5-mm sections. Deparaffinized sections were autoclaved at
120uC for 1 min, immersed in 0.3% H202 and rinsed with 1xPBS
before incubation overnight at 4uC with each of the primary
antibodies. The sections were rinsed with 1xPBS and incubated
with the secondary antibody (Simple Stain MAX-PO; Nichirei,
Japan) at room temperature for 1 hour. The sections were then
stained with 3,39-diaminobenzidine tetrahydrochloride (DAB),
and counter-stained with hematoxylin.
Microscopic evaluation
At first, we had classified into 3 categories: I, negative stain in
both cytoplasm and nuclei; II, positive stain only in cytoplasm and
negative in nuclei; III, positive stain in nuclei and/or cytoplasm.
However, our recent study proved that RB1 expression was
significantly higher in the cases with nuclear RB1CC1 expression
(grade III) than in the cases without nuclear RB1CC1 (grade I and
II) [4]. Therefore, RB1CC1 staining grades I-II and III were
defined as -negative (2) and -positive (+), respectively. A
dysfunctional status of p53 was assessed immunohistochemically
by the percentage of cells that were positive for p53 and p21. An
abnormal p53 status (p53ab) was defined as a case of breast cancer
when more than 50% of tumor cells were strongly positive for p53,
while less than 10% of the cells were positive for p21. Nuclear
expressions of p16 and p21 in tumor cells were recognized as
positive labels.
Statistical analysis of difference between RB1CC1 and the
other indicators
Student’s t-test was used to evaluate the relationships between
RB1CC1 staining and the labeling indices of RB1, p16, p21 and
Ki-67. A p-value of ,0.05 was considered statistically significant.
Supporting Information
Figure S1 RB1CC1 interacts with hSNF5 and p53 mainly in
cell nuclei. (A) RB1CC1 (green), hSNF5 (red), p53 (blue) and the
merged image in MCF-7 cells. Each protein is immunofluores-
cently labeled by Alexa 488, 594 or 350 respectively. Scale bar,
50mm. (B) RB1CC1 (green), DAPI and the merged image are
evaluated in MCF-7 cells. RB1CC1 is immuno-labeled by Alexa
488, and DAPI is displayed with blue fluorescence in cell nuclei.
Scale bar, 50mm.
Found at: doi:10.1371/journal.pone.0011404.s001 (0.90 MB TIF)
Figure S2 Modulation of RB1CC1 affects the growth of breast
cancer cells through RB1, p21 and/or p16 expression. (A) In
MCF-7 breast cancer cells, RB1CC1 induced RB1, p53 and p21
expression, and, conversely, the knockdown (sh-RB1CC1) reduced
their expression. (B) RB1CC1 suppressed and sh-RB1CC1
enhanced the cell growth of MCF-7. (C) In SK-BR3 breast
cancer cells, RB1CC1 induced RB1, hSNF5, p16 and p21
expression. sh-RB1CC1 decreased the p16 and p21 contents. (D)
RB1CC1 suppressed and sh-RB1CC1 enhanced the cell growth of
SK-BR3. A and C indicate the Western blots data. B and D show
the results of cell growth assays. Modulation was performed by
lentiviral transduction of cDNA or sh-RNA of RB1CC1 into the
cells. pLenti6 and sh-GL3 were used as controls. The experiments
were performed in triplicate. Representative immunoblots, plates
and mean colony numbers 6 standard errors are shown. (E) After
the lentiviral modification of RB1CC1 expression, HeLa cells were
analyzed by flow cytometry. RB1CC1 and sh-RB1CC1 are
indicated by red (left) and blue (right), respectively. The data
(mean percentages 6 standard deviations) were confirmed in
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is demonstrated. Arrows indicate whether statistically significant
increases (up-arrow) or decreases (down-arrow) are present
according to the Student’s t-test; p,0.05.
Found at: doi:10.1371/journal.pone.0011404.s002 (0.68 MB TIF)
Table S1 The primer sequences and conditions for ChIP-PCR
and RT-PCR.
Found at: doi:10.1371/journal.pone.0011404.s003 (0.04 MB
DOC)
Acknowledgments
We are grateful to Masashi Saji, Hiroko Kita and Sawako Hirayama for
experimental assistance.
Author Contributions
Conceived and designed the experiments: TC HO. Performed the
experiments: TC KI YO HT IN KM TI. Analyzed the data: TC KI
YO HT YT YJ HI MI KT IN KM HI TI HO. Contributed reagents/
materials/analysis tools: TC YT YJ HI MI KT HI TI MS TS YH. Wrote
the paper: TC KI HO.
References
1. Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25:
5220–5227.
2. Chano T, Ikegawa S, Kontani K, Okabe H, Baldini N, et al. (2002)
Identification of RB1CC1, a novel human gene that can induce RB1 in various
human cells. Oncogene 21: 1295–1298.
3. Chano T, Kontani K, Teramoto K, Okabe H, Ikegawa S (2002) Truncating
mutations of RB1CC1 in human breast cancer. Nat Genet 31: 285–288.
4. Ikebuchi K, Chano T, Ochi Y, Tameno H, Shimada T, et al. (2009) RB1CC1
activates the promoter and expression of RB1 in human cancer. Int J Cancer
125: 861–867.
5. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, et al. (2003)
From latent disseminated cells to overt metastasis: genetic analysis of systemic
breast cancer progression. Proc Natl Acad Sci U S A 100: 7737–7742.
6. Melkoumian ZK, Peng X, Gan B, Wu X, Guan JL (2005) Mechanism of cell
cycle regulation by FIP200 in human breast cancer cells. Cancer Res 65:
6676–6684.
7. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE (2002) Re-
expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest
associated with induction of p16ink4a and activation of RB. Oncogene 21:
5193–5203.
8. Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, et al. (2002) SWI/SNF complex
interacts with tumor suppressor p53 and is necessary for the activation of p53-
mediated transcription. J Biol Chem 277: 22330–22337.
9. Chai J, Charboneau AL, Betz BL, Weissman BE (2005) Loss of the hSNF5 gene
concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated
with replicative senescence in A204 rhabdoid tumor cells. Cancer Res 65:
10192–10198.
10. Gresh L, Bourachot B, Reimann A, Guigas B, Fiette L, et al. (2005) The SWI/
SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte
differentiation. Embo J 24: 3313–3324.
11. Sakai T, Ohtani N, McGee TL, Robbins PD, Dryja TP (1991) Oncogenic germ-
line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature
353: 83–86.
12. Martin N, Schwamborn K, Urlaub H, Gan B, Guan JL, et al. (2008) Spatial
interplay between PIASy and FIP200 in the regulation of signal transduction
and transcriptional activity. Mol Cell Biol 28: 2771–2781.
13. Hara T, Takamura A, Kishi C, Iemura S, Natsume T, et al. (2008) FIP200, a
ULK-interacting protein, is required for autophagosome formation in
mammalian cells. J Cell Biol 181: 497–510.
14. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, et al. (2009) Nutrient-
dependent mTORC1 Association with the ULK1-Atg13-FIP200 Complex
Required for Autophagy. Mol Biol Cell 20: 1981–1991.
15. Hara T, Mizushima N (2009) Role of ULK-FIP200 complex in mammalian
autophagy: FIP200, a counterpart of yeast Atg17? Autophagy 5: 85–87.
16. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, et al. (2009)
Autophagy mediates the mitotic senescence transition. Genes Dev 23: 798–803.
1 7 .C h a n oT ,S a j iM ,I n o u eH ,M i n a m iK ,K o b a y a s h iT ,e ta l .( 2 0 0 6 )
Neuromuscular abundance of RB1CC1 contributes to the non-proliferating
enlarged cell phenotype through both RB1 maintenance and TSC1 degrada-
tion. Int J Mol Med 18: 425–432.
18. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and
regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
19. Yagi A, Hasegawa Y, Xiao H, Haneda M, Kojima E, et al. (2003) GADD34
induces p53 phosphorylation and p21/WAF1 transcription. J Cell Biochem 90:
1242–1249.
RB1CC1 Activates RB1 Pathway
PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e11404